NCT01860742 - Randomized Phase III of PRRT Versus Interferon | Biotech Hunter

Timeline

Start Date

December 31, 2014

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions

Gastro-intestinal Neuroendocrine Tumors

Interventions

DRUG

Interferon alpha-2b

Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day

DRUG

177Lu-DOTATATE

177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution

Trial Locations (2)

B-1000

Jules Bordet Institute, Brussels

B-3000

UZ Leuven, Leuven